Capricor Therapeutics, Inc. Stock Analysis & AI Score
Capricor Therapeutics, Inc. (CAPR) has an ST Score of 39.1 (C), driven by its Forecast (B) and held back by its Sentiment (F). Analysts rate it Buy with a $12.70 price target (+92.1% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
AI Daily Briefing
Analysis by AICAPR Stock Price History
CAPR Technical Indicators
FMPEarnings Surprises
Analyst Forecast
Revenue Mix
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Analyst Price Target
ESG Score
CAPR Latest Stock News
ST Score
Capricor Therapeutics, Inc. (CAPR) has an ST Score of 39.1 (C), driven by its Forecast (B) and held back by its Sentiment (F). Analysts rate it Buy with a $12.70 price target (+92.1% upside).
- Strongest
- ForecastB
- Weakest
- SentimentF
All factor grades
- ForecastB
- ValuationB-
- ProfitabilityB-
- MomentumB-
- Financial StrengthC
- GrowthD+
- SentimentF
- Piotroski2/9
Press Releases
Company Contact Details
CAPR stock: frequently asked questions
What is CAPR's ST Score?
Capricor Therapeutics, Inc. (CAPR) has an ST Score of 39.1 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is CAPR a buy, hold, or sell?
Analysts rate CAPR a Buy, with a price target of $12.70 (+92.1% vs the current price). Our ST Score grades it C (39.1/100). The ST Score is a data-driven signal, not a recommendation.
What are CAPR's factor grades?
Valuation B-, Profitability B-, Financial Strength C, Momentum B-, Growth D+, Forecast B, Sentiment F.
What is CAPR's valuation grade?
Capricor Therapeutics, Inc. (CAPR) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is CAPR's growth grade?
Capricor Therapeutics, Inc. (CAPR) earns a growth grade of D+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is CAPR's profitability grade?
Capricor Therapeutics, Inc. (CAPR) earns a profitability grade of B-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is CAPR's financial strength grade?
Capricor Therapeutics, Inc. (CAPR) earns a financial strength grade of C, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for CAPR?
The average analyst price target for Capricor Therapeutics, Inc. (CAPR) is $12.70 from 10 analysts, which is +92.1% versus the recent price of $6.61.
What is CAPR's Piotroski score?
Capricor Therapeutics, Inc. (CAPR) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.